

Frank Erhard Uschner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4196287/publications.pdf>

Version: 2024-02-01

49
papers

1,629
citations

257450

24
h-index

315739

38
g-index

50
all docs

50
docs citations

50
times ranked

2249
citing authors

#	ARTICLE	IF	CITATIONS
1	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	3.7	149
2	Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis. <i>Scientific Reports</i> , 2015, 5, 12931.	3.3	127
3	Circulating microbiome in blood of different circulatory compartments. <i>Gut</i> , 2019, 68, 578-580.	12.1	120
4	Quantification of Liver Fibrosis at T1 and T2 Mapping with Extracellular Volume Fraction MRI: Preclinical Results. <i>Radiology</i> , 2018, 288, 748-754.	7.3	96
5	Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 31-41.	8.1	75
6	Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study). <i>Journal of Hepatology</i> , 2021, 75, 1346-1354.	3.7	69
7	Statins improve NASH via inhibition of RhoA and Ras. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, G724-G733.	3.4	61
8	Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis. <i>Gut</i> , 2017, 66, 145-155.	12.1	58
9	Rationale for the use of statins in liver disease. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 312, G407-G412.	3.4	52
10	Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018). <i>Lancet Regional Health - Europe</i> , The, 2022, 12, 100240.	5.6	50
11	Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation. <i>Gut</i> , 2021, 70, gutjnl-2019-320170.	12.1	47
12	Cardiodynamic state is associated with systemic inflammation and fatal acute-on-chronic liver failure. <i>Liver International</i> , 2020, 40, 1457-1466.	3.9	46
13	Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension. <i>Scientific Reports</i> , 2015, 5, 14573.	3.3	45
14	Acute decompensation boosts hepatic collagen type III deposition and deteriorates experimental and human cirrhosis. <i>Hepatology Communications</i> , 2018, 2, 211-222.	4.3	45
15	Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS. <i>Gut</i> , 2020, 69, 1535-1536.	12.1	42
16	Compartmentalization of Immune Response and Microbial Translocation in Decompensated Cirrhosis. <i>Frontiers in Immunology</i> , 2019, 10, 69.	4.8	40
17	The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats. <i>Scientific Reports</i> , 2018, 8, 9372.	3.3	39
18	Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease. <i>Gut</i> , 2022, 71, 402-414.	12.1	39

#	ARTICLE	IF	CITATIONS
19	Combination of CCl ₄ with alcoholic and metabolic injuries mimics human liver fibrosis. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, G182-G194.	3.4	37
20	Interplay of Matrix Stiffness and c-SRC in Hepatic Fibrosis. <i>Frontiers in Physiology</i> , 2015, 6, 359.	2.8	35
21	Hemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AVE0991 in Liver Cirrhosis. <i>PLoS ONE</i> , 2015, 10, e0138732.	2.5	29
22	Systemic MCP-1 Levels Derive Mainly From Injured Liver and Are Associated With Complications in Cirrhosis. <i>Frontiers in Immunology</i> , 2020, 11, 354.	4.8	27
23	Left Ventricular Longitudinal Contractility Predicts Acute-to-Chronic Liver Failure Development and Mortality After Transjugular Intrahepatic Portosystemic Shunt. <i>Hepatology Communications</i> , 2019, 3, 340-347.	4.3	26
24	Rho-kinase inhibitor coupled to peptide-modified albumin carrier reduces portal pressure and increases renal perfusion in cirrhotic rats. <i>Scientific Reports</i> , 2019, 9, 2256.	3.3	26
25	Quantitative liver MRI including extracellular volume fraction for non-invasive quantification of liver fibrosis: a prospective proof-of-concept study. <i>Gut</i> , 2018, 67, 593-594.	12.1	25
26	Dynamic human liver proteome atlas reveals functional insights into disease pathways. <i>Molecular Systems Biology</i> , 2022, 18, e10947.	7.2	22
27	The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension. <i>Oncotarget</i> , 2018, 9, 36220-36237.	1.8	20
28	Novel Rat Model of Repetitive Portal Venous Embolization Mimicking Human Non-Cirrhotic Idiopathic Portal Hypertension. <i>PLoS ONE</i> , 2016, 11, e0162144.	2.5	16
29	Mouse and Rat Models of Induction of Hepatic Fibrosis and Assessment of Portal Hypertension. <i>Methods in Molecular Biology</i> , 2017, 1627, 91-116.	0.9	16
30	Hepatic inflammasome activation as origin of Interleukin-1 α and Interleukin-1 β in liver cirrhosis. <i>Gut</i> , 2021, 70, 1799-1800.	12.1	14
31	The Role of Macrophage-Inducible C-Type Lectin in Different Stages of Chronic Liver Disease. <i>Frontiers in Immunology</i> , 2020, 11, 1352.	4.8	13
32	Quantification of liver fibrosis: extracellular volume fraction using an MRI bolus-only technique in a rat animal model. <i>European Radiology Experimental</i> , 2019, 3, 22.	3.4	12
33	Sex specificity of kidney markers to assess prognosis in cirrhotic patients with TIPS. <i>Liver International</i> , 2020, 40, 186-193.	3.9	12
34	TGR(mREN2)27 rats develop non-alcoholic fatty liver disease-associated portal hypertension responsive to modulations of Janus-kinase 2 and Mas receptor. <i>Scientific Reports</i> , 2019, 9, 11598.	3.3	10
35	Recent Advances in Practical Methods for Liver Cell Biology: A Short Overview. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2027.	4.1	10
36	Combination of phosphodiesterase-5 inhibitors and beta blockers improves experimental portal hypertension and erectile dysfunction. <i>Liver International</i> , 2020, 40, 2228-2241.	3.9	9

#	ARTICLE	IF	CITATIONS
37	Interleukin-22 in acute-on-chronic liver failure: A matter of ineffective levels, receptor dysregulation or defective signalling?. <i>Journal of Hepatology</i> , 2020, 73, 980-982.	3.7	8
38	Variation in Bile Microbiome by the Etiology of Cholestatic Liver Disease. <i>Liver Transplantation</i> , 2020, 26, 1652-1657.	2.4	8
39	Î ² -Arrestin2 is increased in liver fibrosis in humans and rodents. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 27082-27084.	7.1	8
40	Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis. <i>PLoS ONE</i> , 2019, 14, e0222840.	2.5	7
41	Short-Term Western Diet Aggravates Non-Alcoholic Fatty Liver Disease (NAFLD) With Portal Hypertension in TGR(mREN2)27 Rats. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3308.	4.1	7
42	Impact of sleeve gastrectomy and dietary change on metabolic and hepatic function in an obesity rat model - Experimental research. <i>International Journal of Surgery</i> , 2020, 75, 139-147.	2.7	7
43	Extrahepatic Surgery in Cirrhosis Significantly Increases Portal Pressure in Preclinical Animal Models. <i>Frontiers in Physiology</i> , 2021, 12, 720898.	2.8	7
44	Pulmonary impairment independently determines mortality in critically ill patients with acute-on-chronic liver failure. <i>Liver International</i> , 2023, 43, 180-193.	3.9	7
45	"Tipping" extracellular matrix remodeling towards regression of liver fibrosis: novel concepts. <i>Minerva Gastroenterology</i> , 2017, 64, 51-61.	0.5	6
46	Variceal bleeding has increased mortality compared to nonvariceal bleeding only in males. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, Publish Ahead of Print, .	1.6	3
47	Role of circulating angiogenin levels in portal hypertension and TIPS. <i>PLoS ONE</i> , 2021, 16, e0256473.	2.5	2
48	Possible Treatment Strategies for Portal Hypertension in Liver Cirrhosis. <i>Current Hepatology Reports</i> , 2016, 15, 271-279.	0.9	0
49	Animal Models When Examining the Gut-Liver Axis. , 2019, , 235-264.		0